U. S. FDA grants clearance for Ion by Intuitive

U. S. FDA grants clearance for Ion by Intuitive

Press releases may be edited for formatting or style | February 20, 2019 Operating Room
SUNNYVALE, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food and Drug Administration (FDA) cleared the Ion™ endoluminal system to enable minimally invasive biopsy in the peripheral lung.

Lung cancer is the world’s leading cause of cancer deaths. Many suspicious lesions found in the lung may be small and difficult to access, which can make obtaining a diagnosis challenging.

“Early lung cancer diagnosis can save lives. Intuitive’s advanced, robotic-assisted, minimally invasive Ion system helps address a challenging aspect of lung biopsy by enabling physicians to obtain tissue samples from deep within the lung,” said Gary Guthart, Intuitive CEO.

New & Refurbished C-Arm Systems. Call 702.384.0085 Today!

Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs

The Ion system uses an ultra-thin articulating robotic catheter that can move 180 degrees in all directions. The outer diameter of the catheter is 3.5 mm, which physicians can navigate through small and tortuous airways to reach nodules in any airway segment within the lung. The Ion system’s flexible biopsy needle (called the Flexision Biopsy Needle) can also pass through very tight bends via Ion’s catheter to collect tissue in the peripheral lung. The catheter’s 2mm working channel can also accommodate other biopsy tools, such as biopsy forceps or cytology brushes, if necessary.

Intuitive developed the system’s fiber optic shape sensor technology to provide the physician with the precise location and shape information of the catheter throughout the navigation and biopsy process.

Intuitive designed the Ion system to easily integrate into existing lung nodule biopsy workflows, as well as existing imaging technology, including fluoroscopy, radial-endobronchial ultrasound, and cone-beam CT.

“The Ion system represents Intuitive’s continued commitment to innovating for minimally invasive care, and extends our focus beyond surgery,” said Guthart. “At Intuitive, we innovate for need, and lung cancer is clearly a global health challenge that requires new modalities of care.”

Intuitive plans to introduce the Ion system in the U.S. in a measured fashion, with customer shipments beginning in the second quarter of 2019.

Intuitive brings more than two decades of leadership in robotic-assisted surgical technology and solutions to this innovative new platform, which supports the company’s mission in the advancement of minimally invasive care.


About Intuitive
Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, Calif., is the pioneer and a global leader in robotic-assisted, minimally invasive surgery. At Intuitive, we believe that minimally invasive care is life-enhancing care. Through ingenuity and intelligent technology, we expand the potential of physicians to heal without constraints.

Intuitive brings more than two decades of leadership in robotic-assisted surgical technology and solutions to its offerings, and develops, manufactures and markets the da Vinci® surgical system and the Ion™ endoluminal system.

You Must Be Logged In To Post A Comment